Enterprise Value
30.69M
Cash
5.817M
Avg Qtr Burn
-3.485M
Short % of Float
0.97%
Insider Ownership
74.79%
Institutional Own.
2.50%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AgenT-797 + botensilimab/balstilimab Details Gastroesophageal adenocarcinomas, Gastric cancer | Phase 2 Data readout | |
AgenT-797 Details Virus-Induced Acute Respiratory Disease Syndrome | Phase 1/2 Update | |
AgenT-797 +/- pembrolizumab/nivolumab Details COVID-19, Acute respiratory distress syndrome, Solid tumor/s, Gastric cancer, Testicular cancer, Cancer, Non-small cell lung carcinoma | Phase 1 Update |